Krsnaa Diagnostics Limited Cash Flow Reinvestment Rate
Krsnaa Diagnostics Limited cash flow reinvestment rate. Krsnaa Diagnostics Limited (KRSNAA) has a Cash Flow Reinvestment Rate of 2.00x as of September 2025, reinvesting Rs1.04 Billion (capex Rs1.04 Billion ) from operating cash flow of Rs518.74 Million. Explore KRSNAA operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Krsnaa Diagnostics Limited (2017–2025)
Cash flow reinvestment rate of Krsnaa Diagnostics Limited from 2017 to 2025. Historical reinvestment intensity for Krsnaa Diagnostics Limited across 9 annual periods. Explore Krsnaa Diagnostics Limited (KRSNAA) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.
Krsnaa Diagnostics Limited Cash Flow Reinvestment Rate by Year (2017–2025)
Krsnaa Diagnostics Limited cash flow reinvestment rate by year from 2017 to 2025. Year-by-year capital reinvestment analysis for Krsnaa Diagnostics Limited. For the full cash flow conversion analysis, see KRSNAA cash flow metrics.
| Year | Reinvestment Rate | Total Reinvested (INR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 2.59x | Rs2.26 Billion | Rs873.27 Million | Rs1.27 Billion | ▼ -80.5% |
| 2024 | 13.26x | Rs3.23 Billion | Rs243.45 Million | Rs1.94 Billion | ▲ +304.2% |
| 2023 | 3.28x | Rs2.50 Billion | Rs763.01 Million | Rs1.41 Billion | ▲ +62.8% |
| 2022 | 2.01x | Rs2.59 Billion | Rs1.28 Billion | Rs1.32 Billion | ▲ +184.8% |
| 2021 | 0.71x | Rs725.37 Million | Rs1.03 Billion | Rs668.40 Million | ▼ -68.2% |
| 2020 | 2.22x | Rs840.27 Million | Rs378.09 Million | Rs767.49 Million | ▼ -35.5% |
| 2019 | 3.44x | Rs2.01 Billion | Rs582.66 Million | Rs997.77 Million | ▲ +19.6% |
| 2018 | 2.88x | Rs944.21 Million | Rs327.85 Million | Rs906.45 Million | ▲ +236.8% |
| 2017 | 0.86x | Rs531.89 Million | Rs621.99 Million | Rs531.89 Million | — |